SU11274

Confirm delete?

SU11274

Zoom

Cat No: 14861

Biochemicals - Kinase Inhibitors

MET is a proto-oncogene which encodes the hepatocyte growth factor receptor c-Met. It has normal roles in morphogenesis, migration, apoptosis, and angiogenesis.{23657} Dysregulation of c-Met occurs in many types of cancer.{23657} SU11274 is a potent, s...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Synonyms:

(3Z)-N-(3-chlorophenyl)-3-[[3,5-dimethyl-4-[(4-methyl-1-piperazinyl)carbonyl]-1H-pyrrol-2-yl]methylene]-2,3-dihydro-N-methyl-2-oxo-1H-indole-5-sulfonamide

Correlated keywords:

inhibitors receptors antagonists cancers apoptosis angiogenesis METs SU11274 SU-11274 potent selective ATPs inhibits inhibitions c-Met c Met cMet tyrosine kinases cells cycles arrest BaF3 transformed oncogene hepatocyte growth factors morphogenesis migration dysregulation cancers

Product Overview:
MET is a proto-oncogene which encodes the hepatocyte growth factor receptor c-Met. It has normal roles in morphogenesis, migration, apoptosis, and angiogenesis.{23657} Dysregulation of c-Met occurs in many types of cancer.{23657} SU11274 is a potent, selective, ATP-competitive inhibitor of c-Met (IC50 = 20 nM).{23656} It has much less or no activity against other receptor tyrosine kinases.{23656} SU11274 induces apoptosis and cell cycle arrest in transformed Ba/F3 cells and cancer cell lines.{23656,23655}

Size	500 µg
Shipping	dry ice
CAS Number	658084-23-2
Molecular Formula	C₂₈H₃₀ClN₅O₄S
SMILES	ClC1=CC(N(C)S(C2=CC=C(NC(/C3=C\C4=C(C)C(C(N5CCN(C)CC5)=O)=C(C)N4)=O)C3=C2)(=O)=O)=CC=C1
Molecular Weight	568,1
Formulation	A crystalline solid
Purity	≥95%
Custom Code	2922.19
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.